Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Controlled, Observer-blinded Study Conducted To Describe The Immunogenicity, Safety, And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To <18 Months Or 18 To <24 Months, And The Safety And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Controlled, Observer-blinded Study Conducted To Describe The Immunogenicity, Safety, And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To <18 Months Or 18 To <24 Months, And The Safety And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine group B (Primary) ; Hepatitis A vaccine inactivated
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer

    • Most Recent Events

    • 04 May 2020 Status changed from active, no longer recruiting to completed.
    • 27 Mar 2020 This trial has been completed in Czech Republic
    • 17 Dec 2018 Planned End Date changed from 1 Mar 2021 to 14 Mar 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top